JPRN-jRCT2080221302未知3 期
CS-747S PhaseIII trial -Double-blinded comparative study for evaluation of efficacy and safety of CS-747S versus clopidogrel bisulfate in subject with acute coronary syndromes who are to undergo percutaneous coronary intervention
DAIICHISANKYO Co.,Ltd.0 个研究点目标入组 1,200 人开始时间: 2010年11月10日最近更新:
试验速览
- 阶段
- 3 期
- 发起方
- 入组人数
- 1,200
研究概览
简要总结
暂无简介。
研究设计
- 研究类型
- Interventional
入排标准
- 年龄范围
- >= 20age old 至 ot applicable（—）
- 性别
- All
入选标准
- •Are 20 or above when informed consent is written.
- •-Have recent acute coronary syndrome defined as a recent history of ischemic symptoms at rest associated with ECG changes consistent with ischemia and/or elevated cardiac enzymes, and are scheduled for PCI.
排除标准
- •-High bleeding risk
- •-Subjects who have severe complication to be treated (e.g. refractory arrhythmia, malignancy)
- •-hepatic disease or renal disorder
研究者
相似试验
未知
3 期
CS-747S PhaseIII trial (elective PCI)JPRN-jRCT2080221511DAIICHISANKYO Co.,Ltd.600
未知
1 期
A randomized, double-blind, placebo-controlled, continuous IV infusion for 96 hours, ascending dose study to assess the safety, pharmacokinetics and pharmacodynamics of CS-4771 in Japanese healthy subjectsHealthy male volunteersJPRN-jRCT2080221894DAIICHISANKYO Co.,Ltd.24
已完成
3 期
PRASTRO-IIIJPRN-jRCT2080224080DAIICHI SANKYO Co.,Ltd.235
招募中
2 期
SK-5307 Phase II/III studyacromegaly and pituitary gigantismJPRN-jRCT2031230524Kenji Asano33
进行中（未招募）
1 期
S1007 is a clinical trial for patients with node positive (1-3 positive nodes) Hormone Receptor-Positive and HER2-Negative Breast Cancer who when tested with the Oncotype DX test are shown to have a recurrence Score (RS) of 25 or Less. Patients will be randomised to receive endocrinetherapy +/- chemotherapy.EUCTR2012-000576-42-IECancer Trials Ireland5,000